333D secures strategic exposure to $5.5 billion AI infrastructure platform
333D has made a $150,000 strategic investment in Firmus Grid Limited, a next-generation AI data centre platform backed by NVIDIA. The investment provides early, capital-efficient exposure to the rapidly expanding AI infrastructure sector ahead of Firmus’s targeted ASX listing in 2026.
Firmus recently completed a US$505 million capital raise led by Coatue Management, valuing the business at approximately US$5.5 billion. The company is constructing Project Southgate, a purpose-built AI factory campus in Launceston, Tasmania, supported by a US$10 billion debt facility arranged with Blackstone.
| Metric | Detail |
|---|---|
| Investment Amount | $150,000 |
| Firmus Valuation | ~US$5.5 billion |
| Firmus Lead Investor | Coatue Management |
| Strategic Backer | NVIDIA |
| Project Financing | US$10 billion (Blackstone) |
For 333D shareholders, the investment provides minority exposure to a credentialled pre-listing AI infrastructure company at institutional-grade valuation. The Firmus platform is positioned at the centre of global demand for AI-driven data processing infrastructure, a sector attracting significant institutional capital as enterprises accelerate AI adoption.
The investment was funded from existing cash reserves. The Board considers the investment not to be material to the Company and confirms it does not constitute a change in the nature of 333D’s activities.
When big ASX news breaks, our subscribers know first
What is AI data centre infrastructure and why does it matter?
AI data centres provide the high-performance computing power required to train and run artificial intelligence models. These facilities differ from traditional data centres by housing specialised hardware designed to handle the intensive computational workloads AI applications demand.
The sector is experiencing structural growth as global AI adoption accelerates across industries. Training large AI models requires massive increases in compute capacity, creating sustained demand for purpose-built infrastructure. This dynamic has attracted significant institutional capital from investors like Coatue Management and infrastructure financing from firms like Blackstone.
Firmus’s Project Southgate exemplifies this buildout, combining NVIDIA’s technology backing with Blackstone’s US$10 billion debt facility to construct a purpose-built AI factory campus in Tasmania. The facility is designed to meet the specific power, cooling, and connectivity requirements of next-generation AI workloads.
For 333D, the investment provides early exposure to this infrastructure buildout before Firmus’s anticipated ASX listing. The company’s pre-listing valuation of approximately US$5.5 billion reflects institutional confidence in the sector’s growth trajectory and Firmus’s positioning within it.
AI clinical software development advances through structured milestones
Parallel to the Firmus investment, 333D has continued to progress its proprietary AI clinical-software development based on DICOM digital assets. The development pathway is structured around a multi-phase technical and regulatory framework aligned with the Therapeutic Goods Administration’s regulatory environment for software-based medical devices.
The development team has completed a major model training and evaluation milestone on a multi-thousand-study dataset of de-identified cone-beam CT (CBCT) scans. The project is currently progressing through pre-deployment optimisation and validation activities.
The dataset was sourced under a data-sharing arrangement with Next Healthcare, as announced on 31 July 2024. Next Healthcare is a company controlled by 333D Chairman John Conidi, and as such, the data-sharing arrangement is governed at arm’s length under the oversight of the Company’s independent directors.
The software product is being developed for application in the dental and maxillofacial imaging market. Potential commercial pathways include:
- Clinical-network integration
- Standalone software offerings
The Board will provide further substantive updates as the project reaches subsequent technical and commercial milestones. This proprietary AI development builds regulated intellectual property with defined commercial pathways, distinct from the passive Firmus investment.
Strategic rationale: applied AI meets AI infrastructure
The Board views the Firmus investment and in-house AI product development as complementary expressions of a single strategic direction. The Firmus investment provides 333D shareholders with direct minority exposure to Australian AI infrastructure at a credentialled pre-listing valuation, while the Company’s proprietary AI development builds intellectual property and a regulated commercial pathway exploiting 333D’s expertise in digital asset management.
The Board notes that together the two initiatives position 333D at the intersection of applied AI and AI infrastructure — a structurally significant theme for global capital markets.
The approach represents targeted, capital-efficient entry into a high-growth sector. It aligns with the Board’s stated focus on disciplined capital allocation toward initiatives where 333D’s existing capabilities and external sector exposure can be combined to create shareholder value.
For shareholders, the dual strategy provides both passive infrastructure exposure through Firmus and active intellectual property development optionality through the clinical software program. The two initiatives target different segments of the AI value chain while leveraging 333D’s core competencies in digital asset creation and management.
Capital position and investment materiality
The Firmus investment was funded from existing cash reserves. The Company’s capital position as at 31 March 2026 provides the following context:
- $150,000 investment amount
- Represents ~18.6% of cash reserves
- Represents ~14.7% of total liquidity
The Board considers the investment not to be material to the Company and confirms it does not constitute a change in the nature of 333D’s activities. The Company retains sufficient liquidity to continue funding its existing operations, including ongoing AI product development.
The investment is sized appropriately to provide sector exposure without compromising operational funding capacity. 333D maintains the financial flexibility to advance its proprietary AI clinical-software development through upcoming technical and regulatory milestones.
What comes next for 333D
Firmus is targeting an ASX listing in 2026, which represents a potential liquidity event or revaluation catalyst for 333D’s investment. The listing timeline positions 333D shareholders to benefit from any re-rating of AI infrastructure assets as the sector matures and market awareness increases.
The Board will provide further substantive updates on AI product development as the project reaches subsequent technical and commercial milestones. Near-term catalysts include progress through TGA-aligned regulatory stages and validation of the CBCT-based clinical software.
The Company’s approach emphasises disciplined capital allocation toward initiatives where existing capabilities and external sector exposure combine to create shareholder value. The Firmus investment and proprietary AI development together position 333D at the intersection of applied AI and AI infrastructure, providing shareholders with exposure to both segments of a structurally significant growth theme.
Want the Next AI Infrastructure Play in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news and in-depth analysis delivered within minutes of release. Click the “Free Alerts” button at StockWire X to get real-time coverage of Tech sector announcements the moment they hit the market.